1. Home
  2. SCYX vs SCOR Comparison

SCYX vs SCOR Comparison

Compare SCYX & SCOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • SCOR
  • Stock Information
  • Founded
  • SCYX 1999
  • SCOR 1999
  • Country
  • SCYX United States
  • SCOR United States
  • Employees
  • SCYX N/A
  • SCOR N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • SCOR Business Services
  • Sector
  • SCYX Health Care
  • SCOR Consumer Discretionary
  • Exchange
  • SCYX Nasdaq
  • SCOR Nasdaq
  • Market Cap
  • SCYX 32.3M
  • SCOR 34.6M
  • IPO Year
  • SCYX 2014
  • SCOR 2007
  • Fundamental
  • Price
  • SCYX $0.79
  • SCOR $8.06
  • Analyst Decision
  • SCYX
  • SCOR
  • Analyst Count
  • SCYX 0
  • SCOR 0
  • Target Price
  • SCYX N/A
  • SCOR N/A
  • AVG Volume (30 Days)
  • SCYX 574.3K
  • SCOR 156.0K
  • Earning Date
  • SCYX 11-05-2025
  • SCOR 11-11-2025
  • Dividend Yield
  • SCYX N/A
  • SCOR N/A
  • EPS Growth
  • SCYX N/A
  • SCOR N/A
  • EPS
  • SCYX N/A
  • SCOR N/A
  • Revenue
  • SCYX $3,257,000.00
  • SCOR $358,513,000.00
  • Revenue This Year
  • SCYX $422.61
  • SCOR $3.45
  • Revenue Next Year
  • SCYX $240.56
  • SCOR $2.59
  • P/E Ratio
  • SCYX N/A
  • SCOR N/A
  • Revenue Growth
  • SCYX N/A
  • SCOR N/A
  • 52 Week Low
  • SCYX $0.66
  • SCOR $4.39
  • 52 Week High
  • SCYX $1.62
  • SCOR $10.18
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 36.53
  • SCOR 61.47
  • Support Level
  • SCYX $0.74
  • SCOR $8.31
  • Resistance Level
  • SCYX $1.14
  • SCOR $10.18
  • Average True Range (ATR)
  • SCYX 0.07
  • SCOR 0.52
  • MACD
  • SCYX -0.04
  • SCOR 0.13
  • Stochastic Oscillator
  • SCYX 11.22
  • SCOR 48.06

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About SCOR comScore Inc.

comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each across media platforms. The platforms it measures include televisions, mobile devices, computers, tablets, CTV devices, and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada, and other regions. It provides solutions for the automotive, digital media, financial services, pharmaceutical, retail, technology, travel, and other industries.

Share on Social Networks: